Pharmaceutical Research
&
Development Consulting
An advisory firm for healthcare companies.
Track record in pharma, biotech, and other healthcare sectors. Professional width in-depth operational and strategic experience.
Pharmaceutical Research
Designing effectiveness models
Preclinical Drug Developement
Pharmacology
In-vivo pharmacology efficacy models (Oncology/Tumormodels)
In-vitro pharmacology models (e.g., Cytotoxicity assays)
Toxicology
General toxicology studies
Genetic toxicology
Developmental and reproductive toxicology studies
Identifying the Best Service Providers for Research & Development
Freelance
Academia
Patent attorneys
Contract Service Organizations
Clinical Drug Developement Phases I-II
Design of a Clinical Development Program (Study Designs)
We have worked in..
Oncology
Immuno-Oncology
Inflammation
Rheumatology
Hepatology
Identifying the Best Service Providers for Clinical Development
Freelance
Academia
Contract Service Organizations
Reseach, knowledge and data
Knowledge base
With information on…
> 2,500 drugs (approved, not-approved)
> 800 diseases
> 2,500 clinical trials
> 5,500 Publications
Regular evaluation of > 50 scientific journals
Visiting international specialist conferences
Data
We carry out database searches
Analyzes
We evaluate service provider offers and analyze study results.
Writing
Concept papers
Teasers
Reports
Study protocols
Special Subject: Intestinal (Gut) Microbiota
The human body is host to trillions of microbes, comprising several hundred species per person residing mainly in the gastrointestinal tract. They are generally in a symbiotic relationship, impart protective functions to the gut, and regulate immunological, metabolic and neuronal functions throughout the body. Disruptions to the microbiome (dysbiosis) are implicated in a host of disorders, malfunctions, and it is now clear that gut microbiota regulate the response to cancer immunotherapies.
We provide answers to the following questions:
- Which types of bacteria, species, subspecies, strains contribute to homeostasis or dysbiosis, and how?
- What influence do lifestyle, environmental impacts, nutrition have on the composition of the intestinal microbiome?
- Which diseases or functional disorders are associated with the reduced or increased occurrence of certain bacteria?
- What influence do messenger substances/metabolites of the bacteria have on diseases or functional disorders?
- How can the microbiome be influenced favorably by drugs, prebiotics, probiotics, synbiotics, medically active substances?
- To what extent are the relationships clinically proven (clinical studies)?
Prof. Dr. Hans Lentzen
Hans Lentzen studied pharmacy at the Johannes Gutenberg University Mainz and received his Ph.D. at the Institute of Pharmacology at the Julius Maximilians University in Würzburg (Germany) in the field of amine transmitter metabolism in CNS synapses. He then carried out research in the department of pharmacology at the Philipps University in Marburg on ATPase-dependent transport processes in yeasts. After moving to Berlin, he stayed for eight years at the Institute of Pharmacology at the Free University of Berlin (Germany), where he habilitated in pharmacology and toxicology with a thesis on glial and neuronal enkephalin metabolism. He started his industrial career at the pharmaceutical company MADAUS (Germany) first as head of experimental research, later as head of research and development. He gained experience in various therapeutic areas (such as hepatology, organ protection, rheumatology, inflammation, immunology, oncology), molecular targets, and drug modalities. In the biotech company VISCUM, which he and a co-founder founded, he deepened his experience in the clinical development of phases I and II in immune-oncology. At the same time, he founded LENTZEN GmbH, where he works as an independent consultant. In addition to his consulting work, he is the managing director of MELEMA Pharma GmbH (Germany).
Contact
Lentzen GmbH
Pharmaceutical Research & Development Consulting.
Amselweg 7
51503 Rösrath